X |
Filing Date |
Trade Date |
Ticker |
Company Name | Insider Name | Title |
Trade Type |
Price |
Qty |
Owned |
ΔOwn |
Value |
1d |
1w |
1m |
6m |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2025-01-16 | IONS | Ionis Pharmaceuticals Inc | Hougen Elizabeth L | EVP, Finance, CFO | S - Sale+OE | $32.81 | -8,870 | 107,885 | -8% | -$290,989 | |||||
2025-01-15 | LNTH | Lantheus Holdings, Inc. | Thrall James H | Dir | S - Sale | $94.76 | -1,000 | 33,207 | -3% | -$94,760 | ||||||
2025-01-16 | NEOG | Neogen Corp | Naemura David H. | CFO | P - Purchase | $11.11 | +14,800 | 61,434 | +32% | +$164,428 | ||||||
2025-01-16 | NEOG | Neogen Corp | Adent John Edward | CEO | P - Purchase | $11.03 | +23,035 | 269,164 | +9% | +$254,076 | ||||||
| M | 2025-01-13 | OCX | Oncocyte Corp | Smith Patrick W | 10% | P - Purchase | $2.12 | +16,055 | 1,789,958 | +1% | +$34,114 | |||||
2025-01-03 | NTLA | Intellia Therapeutics, Inc. | Dube Michael P | VP, Chief Accounting Officer | S - Sale | $12.18 | -1,372 | 45,640 | -3% | -$16,711 | ||||||
2025-01-03 | NTLA | Intellia Therapeutics, Inc. | Basta James | EVP, GC | S - Sale | $12.18 | -7,074 | 74,497 | -9% | -$86,161 | ||||||
2025-01-03 | NTLA | Intellia Therapeutics, Inc. | Lebwohl David | EVP, Chief Medical Officer | S - Sale | $12.18 | -9,557 | 87,666 | -10% | -$116,404 | ||||||
2025-01-03 | NTLA | Intellia Therapeutics, Inc. | Hicks Derek | EVP, Chief Business Officer | S - Sale | $12.18 | -6,502 | 59,878 | -10% | -$79,194 | ||||||
2025-01-03 | NTLA | Intellia Therapeutics, Inc. | Leonard John M | Pres, CEO | S - Sale | $12.18 | -26,807 | 999,530 | -3% | -$326,509 | ||||||
2025-01-03 | NTLA | Intellia Therapeutics, Inc. | Sepp-Lorenzino Laura | EVP, Chief Scientific Officer | S - Sale | $12.18 | -8,966 | 77,388 | -10% | -$109,206 | ||||||
| M | 2025-01-02 | NTLA | Intellia Therapeutics, Inc. | Clark Eliana | EVP, Chief Technical Officer | S - Sale | $12.17 | -7,978 | 64,048 | -11% | -$97,089 | |||||
2024-12-26 | OCX | Oncocyte Corp | Smith Patrick W | 10% | P - Purchase | $2.13 | +90,219 | 1,773,903 | +5% | +$192,166 | ||||||
2024-12-26 | OCX | Oncocyte Corp | Arno Andrew | Dir | P - Purchase | $2.11 | +12,500 | 97,162 | +15% | +$26,350 | ||||||
2024-12-11 | QDEL | Quidelortho Corp | Blaser Brian J. | Pres, CEO | P - Purchase | $41.42 | +6,033 | 6,033 | New | +$249,878 | ||||||
2024-12-09 | VNRX | Volitionrx Ltd | Innes Guy Archibald | Dir | P - Purchase | $0.57 | +174,764 | 2,991,099 | +6% | +$100,000 | ||||||
2024-12-09 | VNRX | Volitionrx Ltd | Still Timothy I | Dir | P - Purchase | $0.57 | +87,382 | 1,487,382 | +6% | +$50,000 | ||||||
2024-12-09 | VNRX | Volitionrx Ltd | Micallef Jacob Vincent | Chief Scientific Officer | P - Purchase | $0.57 | +43,691 | 487,465 | +10% | +$25,000 | ||||||
2024-12-09 | VNRX | Volitionrx Ltd | Reynolds Cameron John | Pres, CEO | P - Purchase | $0.57 | +139,811 | 3,159,198 | +5% | +$80,000 | ||||||
2024-12-05 | OCX | Oncocyte Corp | James Andrea S. | CFO | P - Purchase | $2.29 | +20,000 | 53,670 | +59% | +$45,800 | ||||||
2024-11-27 | IDXX | Idexx Laboratories Inc /de | Vandebroek Sophie V. | Dir | S - Sale | $420.44 | -344 | 905 | -28% | -$144,630 | ||||||
2024-11-15 | LNTH | Lantheus Holdings, Inc. | Marshall Robert J. Jr. | CFO, Treasurer | S - Sale | $81.20 | -10,000 | 102,963 | -9% | -$812,000 | ||||||
2024-11-14 | LNTH | Lantheus Holdings, Inc. | Blanchfield Paul | Pres | S - Sale | $79.65 | -2,000 | 96,737 | -2% | -$159,300 | ||||||
2024-11-08 | LNTH | Lantheus Holdings, Inc. | Heino Mary Anne | Dir | S - Sale | $87.16 | -11,487 | 611,290 | -2% | -$1,001,218 | ||||||
2024-11-11 | CLDX | Celldex Therapeutics, Inc. | Marucci Anthony S | Pres, CEO | P - Purchase | $26.82 | +11,500 | 40,284 | +40% | +$308,430 | ||||||
2024-10-11 | NEOG | Neogen Corp | Adent John Edward | CEO | P - Purchase | $13.80 | +14,500 | 216,477 | +7% | +$200,100 | ||||||
2024-10-11 | MYGN | Myriad Genetics Inc | Diaz Paul J | Pres, CEO | S - Sale | $22.93 | -15,000 | 962,378 | -2% | -$343,950 | ||||||
| A | 2024-09-06 | CDIO | Cardio Diagnostics Holdings, Inc. | Dogan Timur | CTO | P - Purchase | $0.29 | +68,965 | 197,310 | +54% | +$20,000 | |||||
| A | 2024-09-06 | CDIO | Cardio Diagnostics Holdings, Inc. | Dogan Meeshanthini | CEO | P - Purchase | $0.29 | +68,965 | 1,655,429 | +4% | +$20,000 | |||||
| A | 2024-09-06 | NUTX | Cardio Diagnostics Holdings, Inc. | Dogan Meeshanthini | CEO | P - Purchase | $0.29 | +68,965 | 1,655,429 | +4% | +$20,000 | |||||
2024-10-02 | OCX | Oncocyte Corp | James Andrea S. | CFO | P - Purchase | $2.97 | +33,670 | 33,670 | New | +$100,000 | ||||||
| D | 2024-10-02 | OCX | Oncocyte Corp | Broadwood Partners, L.P. | 10% | P - Purchase | $2.95 | +1,315,339 | 12,488,967 | +12% | +$3,877,619 | |||||
2024-10-02 | NTLA | Intellia Therapeutics, Inc. | Dube Michael P | VP, Chief Accounting Officer | S - Sale | $19.01 | -2,012 | 47,012 | -4% | -$38,248 | ||||||
| A | 2024-09-06 | NUTX | Cardio Diagnostics Holdings, Inc. | Dogan Timur | CTO | P - Purchase | $0.29 | +68,965 | 197,310 | +54% | +$20,000 | |||||
2024-09-11 | MYGN | Myriad Genetics Inc | Diaz Paul J | Pres, CEO | S - Sale | $26.72 | -15,000 | 977,378 | -2% | -$400,800 | ||||||
2024-09-11 | MYGN | Myriad Genetics Inc | Muzzey Dale | Chief Scientific Officer | S - Sale | $26.17 | -2,100 | 108,013 | -2% | -$54,961 | ||||||
2024-09-06 | CDIO | Cardio Diagnostics Holdings, Inc. | Philibert Robert | Chief Medical Officer | P - Purchase | $0.29 | +34,075 | 1,683,867 | +2% | +$9,763 | ||||||
2024-09-09 | MYGN | Myriad Genetics Inc | Dreismann Heinrich | Dir | S - Sale | $27.05 | -10,000 | 121,648 | -8% | -$270,520 | ||||||
2024-09-06 | CDIO | Cardio Diagnostics Holdings, Inc. | Dogan Meeshanthini | CTO | P - Purchase | $0.29 | +68,965 | 197,310 | +54% | +$20,000 | ||||||
2024-09-06 | CDIO | Cardio Diagnostics Holdings, Inc. | Dogan Meeshanthini | CEO | P - Purchase | $0.29 | +68,965 | 1,683,867 | +4% | +$20,000 | ||||||
| A | 2024-02-02 | IONS | Ionis Pharmaceuticals Inc | Hougen Elizabeth L | EVP, Finance, CFO | S - Sale | $49.54 | -2,162 | 92,868 | -2% | -$107,105 | |||||
2024-09-03 | MYGN | Myriad Genetics Inc | Reitan Colleen F | Dir | S - Sale | $27.95 | -46,012 | 42,533 | -52% | -$1,285,851 | ||||||
2024-08-21 | LNTH | Lantheus Holdings, Inc. | Thrall James H | Dir | S - Sale | $98.52 | -1,000 | 34,207 | -3% | -$98,520 | ||||||
2024-08-21 | MYGN | Myriad Genetics Inc | Ancona Margaret | SVP, Chief of Staff | S - Sale | $27.82 | -11,538 | 79,366 | -13% | -$320,987 | ||||||
2024-08-20 | VNRX | Volitionrx Ltd | Innes Guy Archibald | Dir | P - Purchase | $0.67 | +150,000 | 2,780,697 | +6% | +$100,500 | ||||||
2024-08-19 | MYGN | Myriad Genetics Inc | Kumar Rashmi | Dir | S - Sale | $28.01 | -7,500 | 77,392 | -9% | -$210,075 | ||||||
2024-08-14 | LNTH | Lantheus Holdings, Inc. | Niedzwiecki Daniel | See Remarks | S - Sale | $97.54 | -2,500 | 77,744 | -3% | -$243,850 | ||||||
2024-08-12 | LNTH | Lantheus Holdings, Inc. | Ber Gerard | Dir | S - Sale | $96.48 | -15,500 | 21,221 | -42% | -$1,495,396 | ||||||
2024-08-08 | LNTH | Lantheus Holdings, Inc. | Blanchfield Paul | Pres | S - Sale | $96.39 | -2,000 | 98,980 | -2% | -$192,780 | ||||||
2024-08-06 | NEOG | Neogen Corp | Tobin James P | Dir | P - Purchase | $16.86 | +3,000 | 23,392 | +15% | +$50,571 | ||||||
2024-08-02 | LNTH | Lantheus Holdings, Inc. | Heino Mary Anne | Dir | S - Sale | $95.50 | -10,481 | 622,777 | -2% | -$1,000,900 | ||||||
| M | 2024-07-15 | LNTH | Lantheus Holdings, Inc. | Sabens Andrea | Chief Accounting Officer | S - Sale | $124.67 | -2,137 | 60,420 | -3% | -$266,417 | |||||
2024-07-12 | TKNO | Alpha Teknova, Inc. | Telegraph Hill Partners Iv, L.P. | 10% | P - Purchase | $1.24 | +12,096,773 | 26,590,636 | +83% | +$14,999,999 | ||||||
2024-07-12 | TKNO | Alpha Teknova, Inc. | Lowell Matthew | CFO | P - Purchase | $1.24 | +40,322 | 128,376 | +46% | +$49,999 | ||||||
2024-07-12 | TKNO | Alpha Teknova, Inc. | Gunstream Stephen | Pres, CEO | P - Purchase | $1.24 | +80,645 | 243,497 | +50% | +$100,000 | ||||||
2024-07-10 | LNTH | Lantheus Holdings, Inc. | Pruden Gary J | Dir | S - Sale | $95.04 | -12,530 | 23,062 | -35% | -$1,190,851 | ||||||
| D | 2024-07-09 | AWH | Aspira Women'S Health Inc. | Schuler Jack W | 10% | P - Purchase | $0.00 | +6,536 | 1,918,692 | 0% | +$0 | |||||
2024-07-01 | NTLA | Intellia Therapeutics, Inc. | Clark Eliana | EVP, Chief Technical Officer | S - Sale | $22.93 | -405 | 71,470 | -1% | -$9,287 | ||||||
2024-06-17 | NTLA | Intellia Therapeutics, Inc. | Verwiel Frank | Dir | S - Sale | $25.00 | -1,505 | 17,948 | -8% | -$37,625 | ||||||
| D | 2024-01-26 | AWH | Aspira Women'S Health Inc. | Schuler Jack W | 10% | P - Purchase | $0.00 | +28,500 | 1,912,156 | +2% | +$0 | |||||
| D | 2024-06-14 | CLDX | Celldex Therapeutics, Inc. | Martin Samuel Bates | SVP, CFO | S - Sale+OE | $35.42 | -17,172 | 28,125 | -38% | -$608,315 | |||||
| D | 2024-06-14 | CLDX | Celldex Therapeutics, Inc. | Crowley Elizabeth | SVP, CPDO | S - Sale+OE | $34.87 | -30,000 | 9,074 | -77% | -$1,045,962 | |||||
2024-06-13 | LNTH | Lantheus Holdings, Inc. | Sabens Andrea | Chief Accounting Officer | S - Sale | $79.77 | -341 | 62,557 | -1% | -$27,202 | ||||||
| D | 2024-06-07 | CLDX | Celldex Therapeutics, Inc. | Crowley Elizabeth | SVP, CPDO | S - Sale+OE | $35.06 | -15,000 | 9,074 | -62% | -$525,873 | |||||
2024-06-07 | CLDX | Celldex Therapeutics, Inc. | Young Diane C. | SVP, Chief Medical Officer | S - Sale | $35.26 | -45,000 | 2,115 | -96% | -$1,586,844 | ||||||
| D | 2024-06-03 | CLDX | Celldex Therapeutics, Inc. | Heath-Chiozzi Margo | SVP of Regulatory Affairs | S - Sale+OE | $33.65 | -58,369 | 13,383 | -81% | -$1,964,088 | |||||
| D | 2024-06-03 | CLDX | Celldex Therapeutics, Inc. | Wright Richard M. | SVP, CCO | S - Sale+OE | $33.72 | -46,844 | 20,833 | -69% | -$1,579,353 | |||||
| D | 2024-06-03 | CLDX | Celldex Therapeutics, Inc. | Jimenez Freddy A. | SVP, GC | S - Sale+OE | $33.60 | -8,006 | 25,924 | -24% | -$269,002 | |||||
| M | 2024-06-03 | MYGN | Myriad Genetics Inc | Spiegelman Daniel K | Dir | S - Sale | $22.05 | -7,576 | 32,917 | -19% | -$167,013 | |||||
2024-05-31 | AWH | Aspira Women'S Health Inc. | Sandford Nicole | CEO | P - Purchase | $2.42 | +9,493 | 70,596 | +16% | +$22,973 | ||||||
2024-05-30 | LNTH | Lantheus Holdings, Inc. | Niedzwiecki Daniel | See Remarks | S - Sale | $79.86 | -12,873 | 80,244 | -14% | -$1,028,038 | ||||||
| D | 2024-05-30 | CLDX | Celldex Therapeutics, Inc. | Heath-Chiozzi Margo | SVP of Regulatory Affairs | S - Sale+OE | $34.07 | -38,719 | 7,094 | -85% | -$1,319,156 | |||||
| D | 2024-05-30 | CLDX | Celldex Therapeutics, Inc. | Martin Samuel Bates | SVP, CFO | S - Sale+OE | $34.05 | -35,000 | 25,128 | -58% | -$1,191,775 | |||||
| D | 2024-05-30 | CLDX | Celldex Therapeutics, Inc. | Cavanaugh Sarah | SVP of Corp Affairs, Admin. | S - Sale+OE | $33.73 | -20,853 | 1,860 | -92% | -$703,334 | |||||
| D | 2024-05-30 | CLDX | Celldex Therapeutics, Inc. | Crowley Elizabeth | SVP, CPDO | S - Sale+OE | $33.64 | -38,597 | 9,074 | -81% | -$1,298,384 | |||||
| D | 2024-05-28 | LNTH | Lantheus Holdings, Inc. | Maeusli Heinz Christoph | Dir | S - Sale+OE | $79.19 | -18,373 | 23,340 | -44% | -$1,454,989 | |||||
2024-05-28 | LNTH | Lantheus Holdings, Inc. | McHugh Julie | Dir | S - Sale | $78.50 | -2,500 | 28,617 | -8% | -$196,250 | ||||||
2024-05-17 | IDXX | Idexx Laboratories Inc /de | Claflin Bruce L. | Dir | S - Sale | $540.80 | -200 | 1,721 | -10% | -$108,160 | ||||||
| M | 2024-05-13 | MYGN | Myriad Genetics Inc | Diaz Paul J | Pres, CEO | S - Sale | $25.14 | -227,844 | 1,066,166 | -18% | -$5,728,763 | |||||
2024-05-13 | MYGN | Myriad Genetics Inc | Newcomer Lee Nisley | Dir | S - Sale | $25.30 | -6,200 | 66,650 | -9% | -$156,860 | ||||||
2024-05-13 | LNTH | Lantheus Holdings, Inc. | Sabens Andrea | Chief Accounting Officer | S - Sale | $76.89 | -341 | 62,898 | -1% | -$26,219 | ||||||
2024-04-15 | LNTH | Lantheus Holdings, Inc. | Sabens Andrea | Chief Accounting Officer | S - Sale | $61.24 | -341 | 63,239 | -1% | -$20,883 | ||||||
2024-04-17 | NEOG | Neogen Corp | Jones Douglas Edward | COO | P - Purchase | $12.36 | +10,000 | 46,131 | +28% | +$123,590 | ||||||
| D | 2024-04-11 | OCX | Oncocyte Corp | Broadwood Partners, L.P. | 10% | P - Purchase | $2.92 | +2,420,000 | 9,858,289 | +33% | +$7,057,688 | |||||
2024-04-11 | OCX | Oncocyte Corp | Riggs Josh | CEO, Pres | P - Purchase | $2.95 | +3,390 | 3,505 | >999% | +$10,001 | ||||||
2024-04-11 | OCX | Oncocyte Corp | Arno Andrew | Dir | P - Purchase | $2.95 | +33,898 | 84,662 | +67% | +$99,999 | ||||||
2024-04-11 | NEOG | Neogen Corp | Borel James C | Dir | P - Purchase | $13.06 | +7,500 | 21,392 | +54% | +$97,986 | ||||||
2024-04-10 | NEOG | Neogen Corp | Naemura David H. | CFO | P - Purchase | $12.51 | +12,500 | 30,040 | +71% | +$156,321 | ||||||
2024-04-10 | NEOG | Neogen Corp | Adent John Edward | CEO | P - Purchase | $12.36 | +23,000 | 152,389 | +18% | +$284,190 | ||||||
2024-03-15 | LNTH | Lantheus Holdings, Inc. | Marshall Robert J. Jr. | CFO, Treasurer | S - Sale | $60.00 | -20,000 | 113,749 | -15% | -$1,200,000 | ||||||
2024-03-13 | LNTH | Lantheus Holdings, Inc. | Sabens Andrea | Chief Accounting Officer | S - Sale | $60.48 | -341 | 63,204 | -1% | -$20,624 | ||||||
2024-03-07 | LNTH | Lantheus Holdings, Inc. | Blanchfield Paul | Pres | S - Sale | $61.96 | -18,023 | 102,857 | -15% | -$1,116,705 | ||||||
2024-03-06 | CATX | Perspective Therapeutics, Inc. | Lantheus Alpha Therapy, LLC | 10% | P - Purchase | $0.95 | +60,431,039 | 116,773,394 | +107% | +$57,409,487 | ||||||
| D | 2024-03-06 | IDXX | Idexx Laboratories Inc /de | Polewaczyk James F | EVP | S - Sale+OE | $558.44 | -8,104 | 10,711 | -43% | -$4,525,596 | |||||
| D | 2024-03-05 | IDXX | Idexx Laboratories Inc /de | Vandebroek Sophie V. | Dir | S - Sale+OE | $562.98 | -1,404 | 9,389 | -13% | -$790,427 | |||||
| DM | 2024-03-05 | LNTH | Lantheus Holdings, Inc. | Leno Sam R | Dir | S - Sale+OE | $64.06 | -4,090 | 57,937 | -7% | -$262,005 | |||||
| D | 2024-03-04 | LNTH | Lantheus Holdings, Inc. | Leno Sam R | Dir | S - Sale+OE | $65.42 | -22,389 | 57,937 | -28% | -$1,464,749 | |||||
| D | 2024-03-04 | ACHV | Achieve Life Sciences, Inc. | Stewart Richard Alistair | Exec COB | P - Purchase | $4.59 | +10,000 | 38,501 | +35% | +$45,850 | |||||
| D | 2024-03-04 | ACHV | Achieve Life Sciences, Inc. | Bencich John | CEO | P - Purchase | $4.59 | +10,000 | 76,724 | +15% | +$45,850 | |||||
2024-03-04 | LNTH | Lantheus Holdings, Inc. | Heino Mary Anne | Dir | S - Sale | $65.31 | -93,863 | 630,623 | -13% | -$6,129,889 |
| A | Amended filing |
| D | Derivative transaction in filing (usually option exercise) |
| E | Error detected in filing |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |